MTOR and germinoma: Therefore, we suspect that the 43.7% of germinomas with no genetic alterations in our study might have alteration in other components of these pathways besides KIT and RAS. This is supported by Ichimura et al. [31] who found 7% of germinomas mutated for MTOR and further tumors mutated in genes of these two pathways.